RE:How much is needed to start Phase I?The following table provides an overview of the estimated expenditures required for the Company to advance its PMN310 monoclonal antibody into a clinical trial and, subject to approval of an IND application, complete Phase 1. The Company cautions readers that such information is forward-looking in nature and is qualified in its entirety by the risk factors and other disclosure set-out under “Risk Factors” and any other factors set forth in the Company’s public disclosure. Further, as preparing, submitting, and advancing applications for regulatory approval, developing products and processes and clinical trials are complex, costly, and time-consuming processes, the Company has only provided an estimated range of the future costs. Amyloid-β Oligomer Use of Existing Cash Resources (Next 12 Months) Preclinical Development (2) Clinical Trial Phase 1 Total Additional Capital (3) PMN310 $1,156,917 (1) $9 Million to $14 Million $14 Million to $24 Million $23 Mill
page 11, short form prospectus